en.Wedoany.com Reported - MannKind Corporation will present new clinical and real-world data on its products Afrezza (human insulin inhalation powder) and FUROSCIX (furosemide injection) at the American Diabetes Association (ADA) 2026 Scientific Sessions. The company is a biopharmaceutical firm focused on chronic disease treatments for cardiometabolic and orphan lung diseases. The conference is being held from June 5 to 8, 2026, in New Orleans, Louisiana, USA. Based on the U.S. Food and Drug Administration (FDA) approval of Afrezza on May 29, 2026, for children and adolescents aged 6 years and older with type 1 and type 2 diabetes, the data presented at the conference further reinforce its safety and efficacy.
Dr. Kevin Kaiserman, Senior Vice President and Head of the Diabetes Therapeutic Area at MannKind Corporation, stated that as the company continues to advance care for diabetes patients, and following the recent approval of Afrezza for children and adolescents aged 6 years and older, the data presented at this year's ADA conference further reinforce its established safety and efficacy, while also highlighting benefits that extend beyond glycemic control into patients' daily lives. The company is committed to expanding meaningful treatment options to help patients better manage diabetes in ways that suit them, and the growing body of Afrezza evidence supports a more personalized and patient-centered approach to care.
A post-hoc analysis from the INHALE-1 study evaluated treatment satisfaction among pediatric participants who achieved glycated hemoglobin (HbA1c) targets. Results showed clinically meaningful improvements in overall treatment satisfaction in the inhaled insulin group, while no significant changes were observed in the rapid-acting insulin analog (RAA) group. Another subgroup analysis from the INHALE-1 study assessed children and adolescent diabetes patients with baseline HbA1c ≤9.5%. After 26 weeks, inhaled insulin achieved non-inferior mean HbA1c compared to RAA, with comparable time in range (TIR) between treatment groups, and adverse event rates similar to adult data.
An interim analysis of a standardized meal challenge compared the safety and efficacy of inhaled insulin and RAA in patients with gestational diabetes mellitus (GDM). Inhaled insulin demonstrated comparable efficacy, with nominally lower postprandial glucose excursions and fewer hypoglycemic events compared to RAA. An exploratory analysis evaluated the use of inhaled insulin in combination with an automated insulin delivery (AID) system for meal and correction doses. Results indicated that glycemic outcomes may vary depending on whether the AID algorithm relies on total daily dose (TDD), with numerically greater A1C reductions observed in systems not dependent on TDD. A new glucose clamp data analysis compared inhaled insulin to insulin lispro, showing that inhaled insulin completed a greater proportion of its pharmacodynamic effect earlier, with over 50% within 60 minutes, compared to only 10% for insulin lispro.
In addition to the above reports, MannKind also presented other analyses, including: dosing strategies and postprandial glycemic control in adult patients with type 1 diabetes, the impact of the Inflation Reduction Act on Afrezza accessibility, a real-world evidence study on the risk of lung cancer incidence in adult patients with type 2 diabetes, and study results evaluating the use of FUROSCIX in patient populations with comorbidities. These data collectively highlight MannKind's ongoing commitment to advancing the clinical understanding of inhaled insulin and supporting personalized diabetes management strategies for both pediatric and adult patient populations.
Michael Castagna, CEO of MannKind Corporation, stated that these new data reflect the company's momentum in diabetes care innovation and its commitment to expanding treatment options for patients aged 6 years and older with diabetes. The company remains focused on advancing its pipeline, expanding accessibility, and providing therapies that better align with patients' real-world needs.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
